Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Does MRI-guided TULSA provide a targeted approach to ablation?

Nature Reviews Urology volume 18, pages 5–6 (2021)Cite this article

Subjects

MRI-guided transurethral ultrasound ablation is an exciting, minimally invasive technology with the potential to provide targeted ablation of prostate cancer tissue. At 3 years, functional outcomes remain good with 76% remaining free from salvage treatment. Future studies using a focal approach may provide evidence for widespread uptake of this technology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Resnick, M. J. et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 368, 436–445 (2013).

    Article  CAS  Google Scholar 

  2. Ahmed, H. U. The index lesion and the origin of prostate cancer. N. Engl. J. Med. 361, 1704–1706 (2009).

    Article  CAS  Google Scholar 

  3. Chin, J. L. et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur. Urol. 70, 447–455 (2016).

    Article  Google Scholar 

  4. Nair, S. M. et al. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective phase I study. BJU Int. https://doi.org/10.1111/bju.15268 (2020).

    Article  PubMed  Google Scholar 

  5. Crouzet, S. et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur. Urol. 65, 907–914 (2014).

    Article  Google Scholar 

  6. Valerio, M. et al. New and established technology in focal ablation of the prostate: a systematic review. Eur. Urol. 71, 17–34 (2017).

    Article  Google Scholar 

  7. Klotz, L. et al. MRI-guided transurethral ultrasound ablation of prostate cancer. J. Urol. https://doi.org/10.1097/JU.0000000000001362 (2020).

    Article  PubMed  Google Scholar 

  8. Shoji, S. et al. Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J. Urol. 190, 1224–1232 (2013).

    Article  Google Scholar 

  9. US National Library of Medicine. ClinicialTrials.gov https://clinicaltrials.gov/ct2/show/NCT03814252 (2020).

Download references

Author information

Authors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

    Rohith Arcot & Thomas J. Polascik

Authors
  1. Rohith Arcot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Polascik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. Polascik.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arcot, R., Polascik, T.J. Does MRI-guided TULSA provide a targeted approach to ablation?. Nat Rev Urol 18, 5–6 (2021). https://doi.org/10.1038/s41585-020-00403-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-020-00403-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer